1c:{"metadata":[["$","title","0",{"children":"NIH VideoCast - Past and Future Therapy for Hepatitis C"}],["$","meta","1",{"name":"description","content":"Wednesday Afternoon Lecture\n

\nAnnual Astute Clinician Lecture \n

\nThe Astute Clinician series honors a U.S. clinician-scientist who has observed an unusual clinical occurrence, and by investigating it, has opened an important new avenue of research. Dr. Jay H. Hoofnagle, an expert in liver diseases, has been involved in early evaluation and development of virtually all antiviral agents developed for viral hepatitis including interferon, ribavirin, lamivudine and adefovir dipivoxil. \n

\nHe has studied Hepatitis C, the most critical area of all liver disease research, for over 30 years. Dr. Hoofnagle will discuss the hepatitis C virus, new insights in how it harms the liver, and new developments of new direct acting antivirals that now promise to cure the majority of patients with this very important liver disease.\n

\n\nFor more information go to http://wals.od.nih.gov"}],["$","meta","2",{"name":"publisher","content":"National Institutes of Health"}],["$","meta","3",{"property":"og:title","content":"NIH VideoCast - Past and Future Therapy for Hepatitis C"}],["$","meta","4",{"property":"og:description","content":"Wednesday Afternoon Lecture\n

\nAnnual Astute Clinician Lecture \n

\nThe Astute Clinician series honors a U.S. clinician-scientist who has observed an unusual clinical occurrence, and by investigating it, has opened an important new avenue of research. Dr. Jay H. Hoofnagle, an expert in liver diseases, has been involved in early evaluation and development of virtually all antiviral agents developed for viral hepatitis including interferon, ribavirin, lamivudine and adefovir dipivoxil. \n

\nHe has studied Hepatitis C, the most critical area of all liver disease research, for over 30 years. Dr. Hoofnagle will discuss the hepatitis C virus, new insights in how it harms the liver, and new developments of new direct acting antivirals that now promise to cure the majority of patients with this very important liver disease.\n

\n\nFor more information go to http://wals.od.nih.gov"}],["$","meta","5",{"property":"og:url","content":"https://uat.d1rkikwu4q8tg.amplifyapp.com/watch/a9a80934-d5db-11f0-9cf9-12c45c580ad9"}],["$","meta","6",{"property":"og:site_name","content":"NIH VideoCast"}],["$","meta","7",{"property":"og:image","content":"https://nihcit.rev.vbrick.com/api/v2/media/videos/thumbnails/c44227bc-180b-4e3e-8d59-9e1a4304e5bd.jpg"}],["$","meta","8",{"property":"og:type","content":"website"}],["$","meta","9",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","10",{"name":"twitter:title","content":"NIH VideoCast - Past and Future Therapy for Hepatitis C"}],["$","meta","11",{"name":"twitter:description","content":"Wednesday Afternoon Lecture\n

\nAnnual Astute Clinician Lecture \n

\nThe Astute Clinician series honors a U.S. clinician-scientist who has observed an unusual clinical occurrence, and by investigating it, has opened an important new avenue of research. Dr. Jay H. Hoofnagle, an expert in liver diseases, has been involved in early evaluation and development of virtually all antiviral agents developed for viral hepatitis including interferon, ribavirin, lamivudine and adefovir dipivoxil. \n

\nHe has studied Hepatitis C, the most critical area of all liver disease research, for over 30 years. Dr. Hoofnagle will discuss the hepatitis C virus, new insights in how it harms the liver, and new developments of new direct acting antivirals that now promise to cure the majority of patients with this very important liver disease.\n

\n\nFor more information go to http://wals.od.nih.gov"}],"$L22","$L23","$L24"],"error":null,"digest":"$undefined"}